Betta Pharmaceuticals Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: Joint Venture, Public, Subsidiary

Established: 2003-01-07

Employees: 1.9K

Market Cap: -

Website: https://www.bettapharma.com

Clinical Trials

Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer

Phase 2

Conditions: Non Small Cell Lung Cancer Stage IIIA
Non Small Cell Lung Cancer Stage IIIB
EGFR Gene Mutation

Interventions: Drug: Icotinib

First Posted Date: 2018-01-10

Last Posted Date: 2018-07-18

Lead Sponsor: Betta Pharmaceuticals Co., Ltd.

Target Recruit Count: 30

Registration Number: NCT03396185

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Science, Beijing, China

Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer

Phase 2

Conditions: EGF-R Positive Non-Small Cell Lung Cancer

Interventions: Drug: Icotinib

First Posted Date: 2017-11-21

Last Posted Date: 2018-07-18

Lead Sponsor: Betta Pharmaceuticals Co., Ltd.

Target Recruit Count: 60

Registration Number: NCT03349203

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Science, Beijing, China

Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer

Phase 2

Conditions: Plasma EGFR Mutation-positive Lung Cancer

Interventions: Drug: Icotinib

First Posted Date: 2017-11-17

Last Posted Date: 2017-11-17

Lead Sponsor: Betta Pharmaceuticals Co., Ltd.

Target Recruit Count: 120

Registration Number: NCT03346811

Locations: 🇨🇳
National Cancer Center/Cancer Hospital, Beijing, Beijing, China

Study of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis

Phase 2

Terminated

Conditions: Mild to Moderate Psoriasis

Interventions: Drug: Icotinib hydrochloride cream
Drug: Placebo cream

First Posted Date: 2017-07-19

Last Posted Date: 2018-11-14

Lead Sponsor: Betta Pharmaceuticals Co., Ltd.

Target Recruit Count: 136

Registration Number: NCT03222622

Locations: 🇨🇳
The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

Phase 2

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: X-396 capsule

First Posted Date: 2017-07-12

Last Posted Date: 2023-08-16

Lead Sponsor: Betta Pharmaceuticals Co., Ltd.

Target Recruit Count: 152

Registration Number: NCT03215693

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳
Peking Union College Hospital, Beijing, China
🇨🇳
Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences, Beijing, China

and more 1 locations

Dose Escalating Study of BPI-3016 in Healthy Subjects

Phase 1

Conditions: Healthy Subject

Interventions: Drug: Placebo
Drug: BPI-3016

First Posted Date: 2017-06-15

Last Posted Date: 2019-01-02

Lead Sponsor: Betta Pharmaceuticals Co., Ltd.

Target Recruit Count: 63

Registration Number: NCT03188848

Locations: 🇨🇳
Beijing Hospital, Beijing, Beijing, China

Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK

Phase 1

Completed

Conditions: Solid Tumor
Non-Small Cell Lung Cancer Metastatic

Interventions: Drug: Ensartinib

First Posted Date: 2016-11-09

Last Posted Date: 2023-08-21

Lead Sponsor: Betta Pharmaceuticals Co., Ltd.

Target Recruit Count: 48

Registration Number: NCT02959619

Locations: 🇨🇳
Sun yat-sen Univerisity Cancer Center, Guanzhou, Guangdong, China

Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC

Phase 1

Recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: BPI-9016M

First Posted Date: 2016-10-11

Last Posted Date: 2021-09-13

Lead Sponsor: Betta Pharmaceuticals Co., Ltd.

Target Recruit Count: 80

Registration Number: NCT02929290

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳
Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
🇨🇳
Affiliated Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang, China

and more 4 locations

Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC Patients

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: BPI-15086

First Posted Date: 2016-09-26

Last Posted Date: 2019-07-18

Lead Sponsor: Betta Pharmaceuticals Co., Ltd.

Target Recruit Count: 36

Registration Number: NCT02914990

Locations: 🇨🇳
Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis

Phase 1

Completed

Conditions: Psoriasis

Interventions: Drug: 1.0% Icotinib hydrochloride cream
Drug: Placebo
Drug: 2.0% Icotinib hydrochloride cream
Drug: 4.0% Icotinib hydrochloride cream
Drug: 0.5% Icotinib hydrochloride cream

First Posted Date: 2016-06-15

Last Posted Date: 2017-07-17

Lead Sponsor: Betta Pharmaceuticals Co., Ltd.

Target Recruit Count: 41

Registration Number: NCT02801435

Locations: 🇨🇳
The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy